|
|
Biblioteca Digital do IPG >
Escola Superior de Saúde (ESS) >
Artigos em Acta de Conferência Internacional (ESS) >
Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10314/3213
|
| Título: | The Economic Burden of Adverse Drug Reactions Leading to and Occurring During Hospitalization |
| Autores: | Bastos, Paulo
Roque, Fátima
Carvajal, Alfonso
Herdeiro, Maria Teresa |
| Palavras Chave: | Adverse Drugs Reactions
costs
medicines use
safety |
| Data: | Oct-2016 |
| Editora: | Drug safety (Adis) |
| Resumo: | Background: Adverse drug reactions (ADRs) are a major public health
problem because they are directly related to mortality, morbidity and costs
[1–3]. Due to their nature and implications, ADRs may account for a
considerable number of hospitalizations, lead to poorer prognostics, and
prolong hospitalization length while increasing the overall direct and
indirect hospitalization-associated costs [4–6].
Objective: To analyze the comparative economic impact of hospitalacquired
ADRs as well as community acquired ADRs leading to hospitalization
and to characterize their associated hospitalization length
and costs, incidence, prevalence, risk factors, predictability, preventability,
most frequently afflicted systems and most common
involved drug groups.
Methods: Systematic analysis performed on PubMed including all studies
published prior to March 30th, 2016. Identified and retrieve studies (1617)
were categorized as case reports, clinical studies, comparative studies,
clinical trials, non-trial clinical studies, other observational studies, multicenter
studies, other evaluation studies or otherwise journal articles. Only
original studies in English or Portuguese language pertaining to adults
and/or the elderly and reporting (as their main goal) cost resulting from
ADRs/ADEs causing hospitalization and/or occurring during hospitalization
were included. Studies performed on the pediatric population, those
restricted to specific diseases (e.g. hypertension, chronic obstructive pulmonary
disease), clinical conditions (e.g. cancer patients, trauma patients)
or drug groups (e.g. antiretroviral therapy, chronic obstructive pulmonary
disease), drug–drug comparative and modeling studies were all excluded
from further analysis.
Results: A total of 1617 studies were retrieved, and 1483 were in human
subjects. 42 % of the studies were classified as Case Reports (n = 23),
Clinical studies (n = 177), Comparative Studies (n = 189), Clinical Trials
(n = 146), Non-Clinical Studies (n = 8), Other Observational Studies (n =
3), Multicenter Studies (n = 62), or Other Evaluation Studies (n = 21). Few
studies pertaining to hospitalization-associated ADRs and resulting cost
existed and were amenable to analysis. Results were reported as mean,
median and/or range and plotted as bar charts.
Conclusion: The economic burden of ADRs is not limited to the direct
hospitalization-associated implications, instead having more extensive
societal implications. While the most commonly prescribed drugs
account for the majority of ADRs, a restricted number of medications
and ADRs account for the majority of the economic burden. Therefore,
identifying and targeting this limited set is of paramount importance to
reduce the health-associated and economic burden resulting from
ADRs. |
| URI: | http://hdl.handle.net/10314/3213 |
| Aparece nas Colecções: | Artigos em Acta de Conferência Internacional (ESTG)
|
Ficheiros deste Registo:
| Ficheiro |
Descrição |
Tamanho | Formato |
|---|
| Drug Safety (2016) 39.pdf | | 658Kb | Adobe PDF | Ver/Abrir | |
|
|
